Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 2,801–2,900 of 2,932
Aljubran, H. J., & Bamalan, O. A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015266
Staphylococcus aureus Cell Envelope as a Target of (‐)‐Globulol
Liu, R., Yang, H., Qi, W., Wang, H., He, X., Yi, Q., & Wang, L. (2026) · Cellular Microbiology · doi:10.1155/cmi/8895641 · Cited by 1
Duah, I. O., Boateng, A. O., Akuffo, K. O., Gyimah, L., & Badu, K. (2026) · Health Science Reports · doi:10.1002/hsr2.72340
“Delayed or incorrect therapy can allow infection to progress into deeper ocular structures, increasing the risk of irreversible visual impairment [4, 11, 12].”
Celia-Sanchez, B. N., Santos, A. R., Chavez, J., Schwem, B. E., Rediguieri, B. C., Misas, E., Parnell, L. A., Lockhart, S. R., & Litvintseva, A. P. (2026) · mSphere · doi:10.1128/msphere.00016-26
Morphological determination of stone-forming salts
Шатохина, И. С., Shatokhina, S. N., & Шабалин, В. Н. (2026) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2026-104-2-136-142
Gu, Q., Chen, Y., Ding, P., He, J., Zhang, H., & Chen, D. (2026) · Drugs · doi:10.1007/s40265-026-02316-y · Cited by 1
“Invasive fungal disease (IFD) causes high mortality and healthcare costs, with invasive aspergillosis (IA) being a common, severe form [1, 2].”
Ortíz, B., Sabater, A. M., Pérez, F., et al. (2026) · BMC Medical Education · doi:10.1186/s12909-026-09207-6
Orcen, A., Doğan, Y., Tulimat, M. A., Göncü, B. S., Erman, B., & Akçapınar, G. B. (2026) · Journal of Fungi · doi:10.3390/jof12050305
“Among these pathogens, filamentous fungi such as Botrytis cinerea are major contributors to crop damage and post-harvest losses [1].”
Shah, D., Martoliya, Y., Mathivathanan, S., Shrivastava, A., Asthana, S., & Varahan, S. (2026) · ACS Infectious Diseases · doi:10.64898/2026.04.23.720332
Lin, C., Cheng, W., Chen, U.-L., Lin, T.-T., Hsu, L.-H., Shih, Y., Lu, I.-H., Chen, Y., & Chen, S.-H. (2026) · ACS Omega · doi:10.1021/acsomega.6c00049
Moola, A., Thom, M. G., Finlay, J. M., Rule, R., & Said, M. (2026) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v41i1.817
Li, M., Liu, Z., Xie, Q., Huang, J., Zhao, M., Zheng, J., & Liao, Y. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100797
Zaragoza, R., Estella, Á., Nuvials, X., Robles-Plaza, M., & Gómez, A. C. (2026) · Journal of Fungi · doi:10.3390/jof12050339 · Cited by 1
“Of these cases, 6.5 million people are affected by an immediately life-threatening fungal disease, and around 2.5 million people die from an FI [1,2].”
InfluentialCheng, D.-H., Pan, H.-P., & Lu, H. (2026) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/4904883
Castro, F. O., Bastos, F., de Oliveira, A. P., de Oliveira, J. M., de Oliveira, A. P., Ferrão, A. R., Pestana, P. G., & Rolo, J. (2026) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002158
“…pathogens normally found in the human microbiota, so many people with underlying health conditions or a weakened immune system, such as chronic illnesses, a history of tuberculosis, human immunodeficiency virus infections and cancer are a vulnerable group for nosocomial fungal infections [5–7].”
Tang, D., Xiong, Q., Wang, Y., Luo, X. H., Jia, J., Feng, Y., & Zhou, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1809671
Antifungal interventions and clinical outcomes: A review
Simran, S., Gaba, P., Sharma, N., & Singh, J. (2026) · Scripta Medica · doi:10.5937/scriptamed57-58699
Kasone, V., Kyokushaba, J., Semanda, P., Namuwenge, P., Oundo, H., Namubiru, S., Najjuka, G., Nantege, G., Nyegenye, W., Nakityo, R., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag302 · Cited by 1
“In 2017, the World Health Organization (WHO) noted that disseminated histoplasmosis is a significant cause of mortality in AIDS patients [1, 2].”
Vahedi‐Shahandashti, R., Nickel, A.-S., Eisele, D., Lass‐Flörl, C., & on behalf of ISHAM Working Group Member of Intrinsic Antifungal Resistance (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01813-25 · Cited by 1
Fungal Infections and Climate Change: Emerging Threats, Future Directions, and Clinical Implications
Chastain, D. B., George, M. E., Cluck, D. B., & Henao‐Martínez, A. F. (2026) · Springer eBooks · doi:10.1007/978-3-032-21237-5_15
Júlio, A. A., Venancio, A. N., de Souza, G. R., da Silva, M. E. G., Parreira, L. A., Aytar, E. C., Ferreira, M. S., Caprini, H. O. G., Soares, M. G., Santos, M. F. C., et al. (2026) · Brazilian Journal of Microbiology · doi:10.1007/s42770-026-01964-2
“Fungal infections have emerged as a serious global pub - lic health concern, accounting for approximately 13 million cases and 1.5 million deaths worldwide [ 43–45].”
InfluentialHydrogel Applications in Treating Skin Diseases: A Gel-Based Approach to Dermatological Therapies
Ahirav, A. M., & Dwivedi, A. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00029
1,2,4-TRIAZOLE DERIVATIVES AS A SOURCE OF NEW ANTIFUNGAL DRUGS
Мартинишин, В. П., Hunchak, V. M., & Rudenko, O. P. (2026) · Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology · doi:10.36359/scivp.2026-27-1.01
Ali, F. G., Abdullah, A. F., Qasim, T. I., & Chasb, H. H. (2026) · Regulatory Mechanisms in Biosystems · doi:10.15421/0226046
Ozturk, S., & Öz, Z. S. (2026) · Pharmaceuticals · doi:10.3390/ph19060817
“Despite the availability of several antifungal agents, including azoles and echinocan-dins, the emergence of antifungal resistance among Candida species has become a serious clinical challenge [11].”
Pulmonary Fungal Infections in Immunocompetent Patients
Arenas-Jiménez, J. J., Franquet, T., Rojas-Varela, R., Arco-Montoro, I., & Ferrandez-Ferrandez, D. (2026) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000889
Ran, J., Zhou, X., Gao, Z., Huan, X., Zeng, M., & Tu, Z. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1843404
Candidiasis in Diabetes: Five-Year Retrospective on Glycaemic Control
Khateb, A. M., Mohammedsaeed, W. M., Shuraym, H. B., & Alghamdi, Z. (2026) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-026-00585-0 · Cited by 1
“These fungus infections can range in severity from asymptomatic, mild mucocutane-ous infections to potentially fatal systemic infections [7].”
Antifungal vaccine development: where we are, where we are headed
Janeczko, M., Kubiński, K., & Wawiórka, L. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128766
Fungicides and neurotoxicity: a neglected risk?
Choudhury, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44287-2.00012-0
Jethani, V., Khanduri, R. S., Khanduri, S., Singh, R., & Goyal, V. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20261696
Glucocorticoid use and candidemia: results from a nationwide case-control study
Leding, C., Meddis, A., Holler, J. G., Astvad, K. M. T., & Benfield, T. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.05.033
Harley, B. K., Ben, I. O., Asamoah, T. D., Amengor, C. D. K., Kortei, N. K., Eghan, P., & Fleischer, T. C. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350399
“Globally, it is estimated that about 35–40% of pregnant women may have vulvovaginal candidiasis with C. albicans responsible for more than 90% of all cases, followed by C. glabrata [46,47].”
Lu, G., Dan, J., Yang, X., Tan, L., & Jiang, J. (2026) · Biosafety and Health · doi:10.1016/j.bsheal.2026.05.006
A Review on Impurity Profiling, Degradation Studies, and Bio-Analytical Method of Anti-Fungal Drugs
Pethani, T. M., Detroja, P., Dave, D., Khan, R., & Mori, D. (2026) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2026.2676681 · Cited by 1
Alam, M. M., & Rayhan, M. Z. (2026) · TAJ Journal of Teachers Association · doi:10.70818/taj.v39i2.0629
Balkrishna, A., Gupta, L., Singh, R., Varshney, Y., Dev, R., Nain, P., Lochab, S., & Varshney, A. (2026) · Food Frontiers · doi:10.1002/fft2.70309
Sahoo, S., Panja, S. C., Dutta, S., et al. (2026) · Journal of Polymer Research · doi:10.1007/s10965-026-04979-3
“Uncontrolled growth may compromise sterility, reduce service life, and increase maintenance requirements [47 ].”
Maqbool, T., Ishaq, H., Shakeel, S., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1717645
Alnuaimi, Y. A. M., Ali, A., Ali, N. E., et al. (2026) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2026.2685287
Management of Infectious Diseases and the Pharmacist’s Role: Fungal Infections
Khan, R. A., Ramadas, A., Makhtar, S. N. A., Osman, M., & Woh-Yon, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00050-4
C. auris in Wastewater: Current Evidence, Risks, One Health Implications, and Knowledge Gaps
Rosa-Machado, A. T., Lopes, B. C., & Mota, C. R. (2026) · ACS Omega · doi:10.1021/acsomega.6c02347 · Cited by 1
The Cytopathology of Infectious Disease: A Review
Michelow, P., & Sriruttan-Nel, C. (2026) · Acta Cytologica · doi:10.1159/000553052
Liu, N., Cheng, M., Tao, Y., Sun, X., Wu, B., Ma, W., Zhou, X., Hong, J., Hu, J., & Cheng, Y. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2537796123 · Cited by 1
Hartl, J., Lehmann, A. D., Wahl, F., & Ralser, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.12.731662
Stack-Couture, S., Marsiglio-Librais, G. N., Lung, B., Genereaux, J. L., Halder, V., Dumeaux, V., Shapiro, R. S., & Lajoie, P. (2026) · Journal of Cell Science · doi:10.1242/jcs.264610 · Cited by 2
“Fungal disease is highly prevalent throughout the human population and causes an estimated 1.6 million deaths per year (Bongomin et al., 2017).”
InfluentialHuman mucormycosis; current perspectives
Thalagala, A. R. P., Gunathilaka, S. S., Bandara, M. W., Adhikari, A. C., Madhuwantha, K. C., & Jayaweera, J. A. A. S. (2026) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000457
Sun, L., Li, J., Li, W.-S., Ren, Z., Yang, Y. S., Liu, W., Zhai, S.-D., Liang, S., & Yu, Z.-H. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02175-3
“Invasive fungal diseases (IFDs) are an increasing global health challenge, particularly among immunocompromised populations [1].”
Braga, M. T., Cartaxo, G. N. J., Passos, J. C. D. S., Moraes, D. N. D., Alberto-Silva, C., & Costa, M. S. (2026) · Molecules · doi:10.3390/molecules31122161
Arı, N., Erten, M., Kayalı, S., et al. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-026-02052-5
VETERİNER İLAÇLARININ ÇEVRESEL KONTAMİNASYONU: GELENEKSEL DERLEME
Kılıç, N., Uzun, K., & Kılıç, N. (2026) · Bozok Veterinary Sciences · doi:10.58833/bozokvetsci.1908083
Zhang, J., Zhang, Y., Feng, X., Wang, T., Xin, J., Yang, W., Xu, W., Sheng, C., & Liu, N. (2026) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2026.2682936
Li, X., Niu, M., Zhang, M., Zheng, Q., Ge, X., Zhang, W., Yu, T., & Zhang, H. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13805-6
“While established literature has identified a rising prevalence of fungal infections driven by increasing cohorts of patients with COPD, AIDS, malignancies, asthma, autoimmune diseases, and transplants [10], our findings offer a more nuanced perspective.”
Hadrich, I., Khemakhem, N., Trabelsi, H., Sellami, H., Elloumi, M., Makni, F., Ayadi, A., & Neji, S. (2026) · Journal of Fungi · doi:10.3390/jof12070466
“Recent epidemiological studies indicate that A. flavus represents a major etiological agent of IA in several geographic regions, particularly in arid and subtropical areas, where its prevalence may equal or even exceed that of A. fumigatus in specific endemic regions [22,23].”
HAC1 contributes to stress adaptation and virulence in the emerging fungal pathogen Candida auris
Oiki, S., Abe, M., Hirasawa, A., Koizumi, A., Otani, A., Shinohara, T., & Miyazaki, Y. (2026) · Medical Mycology · doi:10.1093/mmy/myag067 · Cited by 1
Singh, H., Latka, C., & Taneja, B. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2691864
A review on antifungal activities of benzoxazoles against Candida Albicans and SAR studies
Swaroop, T. R., Suresh, R. N., Basappa, B., & Rangappa, K. S. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00837-9
“In addition, serious infections are also possible during corticosteroid therapies and organ transplantation [2].”
Osman, M. R., Azid, A., Samsudin, M. S., Yunus, K., & Rani, N. L. A. (2026) · Vietnam Journal of Science and Technology/Science and Technology · doi:10.15625/2525-2518/22424
“Similarly, fungal spores such as Aspergillus , frequently found in damp indoor spaces, are a major cause of aspergillosis and contribute to a substantial global disease burden among immunocompromised patients [36].”
Govindan, I., Rama, A., Kailas, A. A., et al. (2026) · Journal of Applied Pharmaceutical Science · doi:10.1177/22313354261427901
Fan, Y., Yang, Q., Zheng, J., Yang, S., Yang, J., & Jia, C. (2026) · Cognitive Computation · doi:10.1007/s12559-026-10622-6
“Fungal infections constitute a major global health burden, affecting millions of people worldwide [ 1–3].”
Candida and Trichosporon species in urban bats from southeastern Brazil
de França, D. A., Menozzi, B. D., & Langoni, H. (2026) · Acta Tropica · doi:10.1016/j.actatropica.2026.108212
Piai, J. M. B., Lippa, V. N. M., Caleffi, E. R., Pangoni, F. B. B., Felipe, M. S., Kioshima, É. S., & Diniz, A. (2026) · ACS Omega · doi:10.1021/acsomega.6c00258
Closing the diagnostic gap to control zoonotic sporotrichosis in the Americas
Souza, C. M., & Rodrigues, M. L. (2026) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2026.101553
Candida spp. suppress neutrophil reactive nitrogen species to evade killing
Burgess, T. B., Hammond, F. R., Szkuta, P. T., Lewis, A., Christou, S., Bowden, K. A., Bicanic, T. A., Prince, L. R., Ayscough, K. R., Partridge, D. G., et al. (2026) · mBio · doi:10.1128/mbio.00202-26 · Cited by 2
“Upregulation of host RNS production via Hif-1α stabilization enhanced host control of C. albicans infection, and this was additive with conventional antifungals.”
Patil, R., Mukherjee, S., Gandham, N. R., Vyawahare, C., Ajagunde, J., Nare, T., Khan, M. S., & Mukhida, S. S. (2026) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_167_25
Fadhil, M. (2026) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2026.07.014
Preda, M., Neacșu, C. L., Popescu, O., et al. (2026) · DNA · doi:10.3390/dna6030033
“Asthma, AIDS, cancer, organ transplantation, and corticosteroid therapy are among the conditions that might lead to serious fungal infections [1,3].”
InfluentialChen, Y., Li, Y., Nahar, K. S., Hind, C. K., Sutton, J. M., & Rahman, K. M. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00330c
De novo lysine synthesis is required for the virulence of Cryptococcus neoformans
Feng, Y., Cui, J., Wang, M., Wang, W., Sun, J., & Liao, G. (2026) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2026.2694879
Oworae, K. O., Rabacal, W., Hu, A., Wychrij, D. A., Rayens, E. A., Chapman, T. I., Bahl, J., & Norris, K. A. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01047-26
“Invasive fungal infections (IFIs), which are life-threat ening account for about 6.5 million cases yearly, resulting in over 3.7 million deaths while non-invasive fungal infections (NIFIs) account for the higher morbidity with over 1 billion affected individuals (1, 4).”
InfluentialFungal keratitis: a persistent challenge in modern ophthalmology
Trojacka, E., Gimenez, J. B., Wróblewska, M., Przybek-Skrzypecka, J., Szaflik, J. P., & Izdebska, J. (2026) · Expert Review of Ophthalmology · doi:10.1080/17469899.2026.2705229
Leong, E. Y. X., Cheong, A. J. Y., Ding, J., et al. (2026) · SAGE Open Medical Case Reports · doi:10.1177/2050313x261465145
“…for invasive aspergillosis due to its favourable side effect profile, superior bone penetration, and improved survival compared to amphotericin B. 19,20 In this case, combination antimicrobial therapy, including oral voriconazole, was necessary due to the polymicrobial nature of the infection.”
Sá, L. G. D. A. V., da Silva, C. R., Neto, J. B. D. A., Rodrigues, D. S., Moreira, L. E. A., Cabral, V. P. D. F., da Silva, W. M. B., Pinheiro, S. D. O., Braga, J. L., Cavalcanti, B. C., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71538
“Human infections caused by fungi, although receiving less attention than bacterial and viral infections, have significant morbidity and mortality rates, causing up to 2 million deaths per year worldwide and affecting approximately 150 million people [1, 2].”
Wu¹, G., Hu², C., Jia, O. Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10301019/v1
The state of mycology in Honduras
Haelewaters, D., Mortier, L., Hofmann, T. A., et al. (2026) · Fungal ecology · doi:10.1016/j.funeco.2026.101533
Ye, R., Liu, M., Zhang, X., Qi, L., Cao, Y., Zhu, C., Yu, H., Zhang, S., & Wang, Y. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1796886
“Candida bloodstream infections account for 50% of such cases in Asia and over 85% of all fungal sepsis cases in Europe and the United States (Bongomin et al., 2017; Cornely et al., 2025).”
Tang, C., Zhang, Y., Belmonte-Lopes, R., Buil, J. B., Pas, S. D., van der Maas, S., Kong, X., Luo, X., Xu, J., Rezaei-Matehkolaei, A., et al. (2026) · The Lancet Microbe · doi:10.1016/j.lanmic.2026.101462
Rosa-Machado, A. T., Carvalho, B. G. P., Fernandes, P., Gonçalves, T., da Mota, J. B., Lopes, B. C., dos Santos, N. J., Fróes, M. C. M., & Mota, C. R. (2026) · Engenharia Sanitaria e Ambiental · doi:10.1590/s1413-4152031s114
Yin, Y., Zhao, Y., Zhao, M., Zhang, L., Li, R., & Liu, L. (2026) · Journal of Fungi · doi:10.3390/jof12080565
“An estimated over 1.5 million life-threatening fungal infections occur worldwide each year, among which filamentous fungal infections account for a substantial proportion and are associated with persistently high mortality rates [5].”
InfluentialSingh, H., Latka, C., Chakraborty, R., Dhingra, L., Bhalla, S., & Taneja, B. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03483-25
Adeyemo, I. A., Ahmed, A. O., Isola, T. O., Aremu, A., Odetokun, I. A., Raufu, I. A., & Raji, M. A. (2026) · BMC Veterinary Research · doi:10.1186/s12917-026-05770-8
Singh, R., Gulati, S., Kumar, S., et al. (2026) · doi:10.1109/gseact68539.2026.11620394
“These factors include socio-economic conditions, geological mapping, ecological spread, and the markers present in the population for high-risk individuals [7].”
Rodrigues, L. S., Barbosa, S. D. C., Chacon, A. P. S., Siqueira, A. C., Bernardi, G., Pillonetto, M., Vicente, V. A., Arend, L. N. V. S., Svidzinski, T. I. E., & Dalla-Costa, L. M. (2026) · Mycopathologia · doi:10.1007/s11046-026-01095-0
“Over the past decade, a global epidemiological shift has been observed, with an increasing incidence of non-albicans Candida species [3].”
Fattahi, S., Dizaj, S. M., Yekani, M., Bahramian, M., Bahramian, A., & Memar, M. Y. (2026) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.70174
Bhatia, N. M., Kumbhar, S. T., Anbhule, P. J., & Bhatia, M. S. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10928-w
FunVFPred: Predicting fungal virulence factors using a unified representation learning model
Kaur, E., & Acharya, V. (2026) · iScience · doi:10.1016/j.isci.2026.117217
Jiang, Y., Dai, S., Pang, R., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1915699
“Although these infections account for only a small fraction of all CNS infections, they are disproportionately lethal (Bongomin et al., 2017).”
Mendoza, A. R., Ramírez, A. P., Encinales, L., Madiedo, O., Carrillo-Encinales, M., Bolívar, J. P. D., Cuellar, J. F. R., Méndez, J. A. U., Moreno-Perilla, Z., & Zambrano, R. J. (2026) · Journal of Fungi · doi:10.3390/jof12080608 · Cited by 1
Kan, M., Yang, F., Zhu, M., Nie, A., Xie, J., & Wang, S. (2026) · Biomedical Chromatography · doi:10.1002/bmc.70600
Novel Therapeutics and Antifungal Agents
Anil, A., Chakrabarti, A., & Rudramurthy, S. M. (2026) · Microbiology & infectious diseases : · doi:10.33590/microbiolinfectdisam/462kwc92
Lemongrass Oil-Based Microemulgel of Luliconazole: Formulation and Antifungal Assessment
Kandekar, U., Suryawanshi, L., Mehetre, S., et al. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs152.057
“Every year, fungal infections caused by the species Candida detrimentally affect around 1.5 million individuals [2,3].”
InfluentialPrevalence of fungal pathogens among respiratory tract infections and associated risk factors
Zahoor, H., Goyal, A., Bhat, P., et al. (2026) · Adesh University Journal of Medical Sciences & Research · doi:10.25259/aujmsr_83_2025
Dual‐Targeting, Hybrid Antifungal Agents Targeting Candida albicans —An Overview
Pal, S. C., Pusti, S., Ansari, I. H., Pradhan, S., Bhattacharya, H., & Das, S. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70380
“Along with three other microorganisms— Candida albicans was placed in the Critical group (World Health Organization 2022) (Howard et al. 2020; Bongomin et al. 2017).”
Yadu, R., Nawange, S. R., & Gumasta, R. (2026) · Journal of Clinical Immunology & Microbiology · doi:10.46889/jcim.2026.7207
“…immunosuppression and structural lung damage in tuberculosis patients create a favorable niche for fungal colonization and subsequent infection [1-3]. https://athenaeumpub.com/journal-of-clinical-immunology-microbiology/ Traditionally, Candida albicans has been regarded as the most predominant…”
Calegari-Alves, Y. P., Cardozo, L. C., Beys‐da‐Silva, W. O., & Santi, L. (2026) · ACS Omega · doi:10.1021/acsomega.6c04202
Valverde-Urrea, M., Defez-Perez, J., Colom, M. F., Terradas, M., Lopez-Llorca, L. V., & Lopez‐Moya, F. (2026) · Marine Drugs · doi:10.3390/md24090296
“Fungal infections are an increasing global health problem, with more than 1.5 million deaths reported annually [1,2].”
InfluentialAchilonu, C. (2026) · Drugs and Drug Candidates · doi:10.3390/ddc5030047 · Cited by 2
Mohammad, S. F., Shahid, T. F., Noor, S., Ahmad, I., Zia, M., Song, H., Shah, S. A., Thiruvengadam, V., Nishan, U., Fawy, K. F., et al. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11178-5
Zhou, L., Hu, L., Pan, L., Feng, L., Huang, J., Tao, Y., Lu, M., Yang, B., & Li, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1911614
Martín‐Loeches, I., & Yu, Y. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2726965
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.